Mariella Spalato Ceruso is an expert in Oncology at Institut Bergonié (France). Mariella Spalato Ceruso has authored 50 publications, the most recent in 2026. SLR score: 188 (community average: 125). How the SLR is computed.

LeadR Profile

Mariella Spalato Ceruso Institut Bergonié France
188 ScienceLeadR Reputation 188
Network Map

Oncology

Subspecialties: Biochemistry - Hematology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2015 - 2026

Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 50

Citations

Citations: 688 1st author: 9 Last author: 0 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Prognostic significance of tumor fraction in advanced sarcoma: highlighting a novel circulating biomarker.
PMID 41699340 — neoplasms, biomarkers, sarcoma, clinical medicine
Clin Exp Med20260
Adenosine A2B Receptor Promotes Tumor Progression and Metastases in Undifferentiated Pleomorphic Sarcoma.
PMID 41642698 — neoplasms, receptor, adenosine a2b, adenosine, sarcoma, neoplasm metastasis, therapeutics
Clin Cancer Res20260
Clinical presentation, management and outcome of 11,132 patients with liposarcoma patients: a population-based study from the NETSARC+ registry.
PMID 40799506 — registries, liposarcoma, incidence, neoplasms, pathology, sarcoma, aged, work, sex, aids-related complex, prognosis
Lancet Reg Health Eur20252
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial.
PMID 40210087 — doxorubicin, neoplasms, drug therapy, maintenance, sarcoma, drug-related side effects and adverse reactions, therapeutics, tissues, chemotherapy
Ann Oncol Top journal20253
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab.
PMID 40579407 — cells, cold temperature, neoplasms, sarcoma, signal transduction, therapeutics, tissues, tumor microenvironment
Signal Transduct Target Ther Top journal20250

LeadR Networks

Main global connection map